Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight

Executive Summary

Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.

Advertisement

Related Content

China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race
Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?
J&J Muscles Into CAR-T Field: Initiates Myeloma Studies
Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel